Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00001174 · ClinicalTrials.gov registry record
Evaluation of the Genetics of Bipolar Disorder
A clinical trial of Bipolar Disorder, sponsored by National Institute of Mental Health (NIMH).
- Active
- Registry status
- 4,185
- Enrollment target
- 1
- Study location
NCT00001174 is a study of Bipolar Disorder that is active but no longer recruiting, run by National Institute of Mental Health (NIMH). The registered enrollment target is 4,185 participants, above the 307-participant average among 162 other Bipolar Disorder trials with a reported enrollment target (1263% higher). The trial reports 1 study location across 1 state.
The verdict
NCT00001174, a study of Bipolar Disorder, is active but no longer recruiting, sponsored by National Institute of Mental Health (NIMH).
- ACTIVE NOT RECRUITING
- Registry status
- 4,185 participants
- Enrollment target
- 1
- Study location
Study Summary
This study looks to identify genes that may affect a person's chances of developing bipolar disorder (BP) and related conditions.
Conditions Studied
Study Locations (1)
Maryland
- National Institutes of Health Clinical Center - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,185 participants |
| Start Date | 1994-08-11 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00001174
The ClinicalTrials.gov registry entry for NCT00001174 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 4,185 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 307-participant average among 162 other Bipolar Disorder trials with a reported enrollment target (1263% higher). The listed sponsor is National Institute of Mental Health (NIMH), which has 343 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Bipolar Disorder appearing as the primary indexed condition, and to 0 interventions.
NCT00001174 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT00001174 about?
NCT00001174 is a clinical study titled "Evaluation of the Genetics of Bipolar Disorder". This study looks to identify genes that may affect a person's chances of developing bipolar disorder (BP) and related conditions.
What is the current status of trial NCT00001174?
This trial is currently active not recruiting. The enrollment target is 4,185 participants. The study started on 1994-08-11.
What conditions does trial NCT00001174 study?
This clinical trial studies the following conditions: Bipolar Disorder.
Who is sponsoring clinical trial NCT00001174?
This trial is sponsored by National Institute of Mental Health (NIMH), which has 343 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00001174 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bipolar Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Taking Action for College Students
RECRUITING · NA
-
A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine
RECRUITING · Phase 3
-
Getting Out of the House: Using Behavioral Activation to Increase Community Participation
RECRUITING · NA
-
Assessing the Impact of Cannabidiol for Anxiety and Depression in Bipolar Disorder
RECRUITING · Phase 2
-
Correcting Circadian Rhythms to Breakthrough in Bipolar Disorder
RECRUITING · Phase 2
-
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.